Skip to main content

Table 2 Patient demographics stratified by no response vs symptom relief with analysis of risk factors associated with clinical effect (Mann-Whitney U test)

From: Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome

 

No response

Symptom relief

p-value

No. patients (%)

9 (25.7)

26 (74.3)

 

Age Mean ± SD

41.0 (9.1)

54.5 (11.8)

0.015

No. gender (%)

 Male

2 (22)

6 (23)

0.959

 Female

7 (78)

20 (77)

 

IC/BPS type (%)

 Type II

6 (66.7)

16 (61.5)

0.644

 Type III

3 (33.3)

10 (38.5)

 

Symptom history (years) Mean ± SD

4.7 (2.2)

5.4 (5.2)

0.516

Pain Scale Mean ± SD

1.7 (0.5)

2.3 (0.8)

0.040

QOL Mean ± SD

5.4 (0.5)

5.7 (0.5)

0.124

Total IPSS Score Mean ± SD

22.8 (5.0)

26.7 (5.0)

0.037

PUF Bother Score Mean ± SD

6.6 (1.3)

7.9 (1.8)

0.065

PUF Symptom Score Mean ± SD

14.4 (2.4)

17.3 (3.3)

0.019

Total PUF Score Mean ± SD

21.0 (3.2)

25.2 (4.8)

0.020

  1. SD Standard deviation, IC/BPS Interstitial cystitis/bladder pain syndrome, IPSS International Prostate Symptom Score, PUF Pelvic Pain and Urgency/Frequency, QOL Quality of life